Translational evidence for the involvement of the endocannabinoid system in stress-related psychiatric illnesses by Matthew N Hill & Sachin Patel
Biology of 
Mood & Anxiety Disorders
Hill and Patel Biology of Mood & Anxiety Disorders 2013, 3:19
http://www.biolmoodanxietydisord.com/content/3/1/19REVIEW Open AccessTranslational evidence for the involvement of the
endocannabinoid system in stress-related
psychiatric illnesses
Matthew N Hill1* and Sachin Patel2*Abstract
Accumulating evidence over the past decade has highlighted an important role of the endocannabinoid (eCB)
system in the regulation of stress and emotional behavior across divergent species, from rodents to humans. The
general findings from this work indicate that the eCB system plays an important role in gating and buffering the
stress response, dampening anxiety and regulating mood. Work in rodents has allowed researchers to determine
the neural mechanisms mediating this relationship while work in human populations has demonstrated the
possible importance of this system in stress-related psychiatric diseases, such as post-traumatic stress disorder,
generalized anxiety and major depression. These stress-protective effects of eCB signaling appear to be primarily
mediated by their actions within corticolimbic structures, particularly the amygdala and the prefrontal cortex. The
aim of this review is to provide an up-to-date discussion of the current level of knowledge in this field, as well as
address the current gaps in knowledge and specific areas of research that require attention.
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For well over half a century investigation of the bio-
logical mechanisms subserving emotional behavior and
affective disorders has focused heavily on the role of
brain monoaminergic signaling. Indeed, dopamine, nor-
epinephrine and serotonin have all been implicated in the
pathophysiology of anxiety disorders and major depressive
disorder, and the vast majority of current pharmacother-
apies for affective illnesses target monoaminergic systems.
However, more recent studies have begun to highlight al-
ternative neurochemical systems in the regulation of
mood and anxiety including neuropeptides, cytokines and
bioactive lipids.
Endogenous cannabinoids (eCBs) are one class of bio-
active lipids produced in the brain and periphery that
exert biological actions via activation of cannabinoid type
1 (CB1) and 2 (CB2) receptors. CB1 receptors are found
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reproduction in any medium, provided the orneurochemical systems, but appear to impact predomin-
ately GABAergic and glutamatergic transmission [1]. CB2
receptors are primarily found on immune cells in the per-
iphery, and to some degree on certain cell types in the
brain, largely microglia, but possibly neurons as well [2].
In addition, some eCB ligands are active at other receptor
targets including peroxisome proliferator-activated recep-
tor (PPAR) and type 1 vanilloid receptor (TRPV1), and
can also directly affect the activity of some ion channels.
Anandamide (AEA) and 2-arachidonoylglycerol (2-AG)
are the two most well-studied eCB ligands and the most
abundant eCBs found in the brain to date. AEA and 2-AG
are synthesized and degraded by distinct enzymatic path-
ways (Figure 1).
In neurons, both AEA and 2-AG can be synthesized in
an activity-dependent manner (Figure 1). Current con-
ceptualizations of synaptic eCB signaling posit that eCBs
are released from postsynaptic neurons during times of
increased neuronal activity and serve to decrease affer-
ent neurotransmitter release in a retrograde manner via
activation of presynaptic CB1 receptors [3] (Figure 1).
eCB synthetic enzymes and CB1 receptors are expressed
in most limbic structures including the prefrontal cortexl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Molecular architecture of endocannabinoid signaling at an excitatory synapse in the brain. 2-AG, 2-arachidonoylglycerol; AEA,
anandamide; CB1, cannabinoid type 1; FAAH, fatty-acid amide hydrolase; MAGL, monoacylglycerol lipase.
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Moreover, synaptic retrograde signaling by eCBs has
been described at glutamatergic and GABAergic synap-
ses in each of these regions. Thus, eCBs are ideally situ-
ated to modulate synaptic integration and efficacy within
limbic neurocircuitry, and thus exert profound effects on
emotional and motivated behaviors.
The signaling life of eCB molecules is maintained by
distinct hydrolytic enzymes, fatty-acid amide hydrolase
(FAAH) and monoacylglycerol lipase (MAGL), which de-
grade AEA and 2-AG, respectively (Figure 1). There is also
a growing belief that AEA and 2-AG may subserve distinct
roles in the regulation of synaptic transmission, with AEA
possessing a gatekeeper like ‘tonic’ role whereby it regu-
lates basal transmission and prevents excess transmitter
release, while 2-AG represents the ‘phasic’ signal that is
brought online during periods of heightened neuronal
activation and mediates most forms of excitation-
induced eCB plasticity [4,5].
Genetic and pharmacological tools have been devel-
oped for the selective study of the role of CB1 receptors
in the regulation of emotional behavior. In addition,
pharmacological and genetic tools to modulate FAAH
and MAGL to dissect the differential biobehavioral ef-
fects of AEA and 2-AG have become increasingly im-
portant in elucidating the role for eCBs in emotional
and motivated behaviors [6]. Moreover, genetic studies
and neuroimaging have begun to advance our knowledge
of the key role eCBs play in the regulation of emotional
responsivity in humans, and in the development of
affective pathology. Here we will review preclinical and
clinical data supporting a role for eCB lipids in the regu-
lation of stress-response physiology, anxiety-like and
depressive-like behaviors, and the adaptations observedin this signaling system in affective disorders in humans.
Key open questions and future directions for preclinical
and clinical research will be presented.
Role of endogenous cannabinoids in emotionality and
stress: preclinical studies
Anxiety-like behaviors
The general consensus of an abundance of preclinical
studies is that eCB signaling constrains anxiety. CB1−/−
mice appear more anxious in the standard behavioral mea-
sures of anxiety including the elevated plus-maze and
light–dark box relative to wild-type mice under aversive
testing conditions [7,8]; while under basal conditions CB1
deletion causes either an anxiogenic effect [9-13] or no ef-
fect [9,14,15]. Moreover, CB1−/− mice are resistant to the
anxiolytic effects of benzodiazepines [11]. Further genetic
dissection of the roles of CB1 receptors on specific neur-
onal subtypes indicate that deletion of the CB1 receptor
from glutamatergic neurons does not affect anxiety in the
elevated plus-maze, but does cause a slight anxiety-like
phenotype in the open field under high environmental
aversiveness [9]. However, genetic deletion of CB1 in
glutamatergic neurons causes more anxiety upon repeated
exposure to the open field under high light conditions,
suggesting a role for CB1 on glutamatergic neurons in the
habituation of anxiety behaviors to repeated exposure to
aversive environments [9]. In contrast, mice lacking CB1
receptors on GABAergic neurons exhibit no differences in
anxiety-like behaviors in the elevated plus-maze [16].
However, conditional mutant mice have revealed that
CB1 receptors located on glutamatergic neurons are
critical for the anxiolytic effects of low doses of exogenous
CB1 receptor agonists, while CB1 receptors expressed
by GABAergic neurons are critical for the anxiogenic
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targeted deletion of CB1 from serotonergic neurons
alone seems to recapitulate the anxiety phenotype of
global CB1−/− mice [17]. Overall, strong converging
genetic studies indicate that CB1 receptors are import-
ant for reducing anxiety, particularly during times of
high environmental aversiveness.
Pharmacological studies have for the most part mir-
rored the data obtained using genetic models. For
example, acute administration of the CB1 receptor
antagonists SR141716 or AM251 increase anxiety-like
behavior in several behavioral measures, including the
elevated plus-maze [18-22], novelty-induced hypophagia
assay [23], social interaction test [24], light–dark box assay
[25] and ultrasonic vocalization assay [26]. However, a few
contradictory reports demonstrate anxiolytic actions of
the CB1 receptor blockade. For example, a CB1 receptor
antagonist reduced anxiety in the elevated plus-maze in
maze-experienced mice [27], reduced some signs of anx-
iety in the defensive probe burying assay [28] and reduced
anxiety associated with alcohol withdrawal [29]. However,
all of these experiments involve an additional manipula-
tion (such as cognitive training or alcohol withdrawal),
which could explain the complex and contradictory effects
of CB1 antagonism on anxiety therein.
The pharmacological blockade of eCB-degrading en-
zymes has been shown to exert anxiolytic actions in a
variety of animal models. The first class of eCB degrad-
ation inhibitors targeted FAAH [30]. Blocking FAAH-
mediated AEA degradation decreases anxiety in the
elevated plus-maze [19,30-35], and the light–dark box
test [36]; importantly, several studies indicate these ef-
fects are enhanced under conditions of high environ-
mental aversiveness [34,37] or following exposure to
stress [38,39]. FAAH inhibition also decreases anxiety in
the rat pup ultrasonic vocalization test [26], light–dark
exploration assay [25] and marble-burying assay [40].
Similarly, FAAH−/− mice exhibit reduced anxiety in the
light–dark box assay and elevated plus-maze during con-
ditions of high aversiveness, but not low stress condi-
tions [31]. Unequivocally, the effects of pharmacological
FAAH inhibition or genetic deletion are blocked by CB1
receptor antagonists [30,31], indicating that FAAH in-
hibition reduces anxiety through augmentation of AEA
signaling at the CB1 receptor.
More recently, MAGL inhibitors that increase brain 2-
AG levels have been evaluated in several models of anx-
iety. The MAGL inhibitor JZL-184 reduces anxiety in
the marble-burying assay [40,41] and elevated plus-
maze, under conditions of high environmental aversive-
ness [35,42-44], but not standard conditions [41]. Both
CB1 and CB2 receptors have been implicated in the
anxiolytic effects of JZL-184 [35,44]. Collectively, these
data indicate that enhancement of eCB signaling,through either potentiation of AEA or 2-AG, reduces
anxiety, particularly when brought on by stress or envir-
onmental aversiveness.
At a circuit level, the effects of eCB signaling on anx-
iety seem to be mediated by CB1 receptor signaling in
the prefrontal cortex and amygdala, two structures com-
monly involved in the regulation of anxiety. Within the
PFC, overexpression of FAAH reduces AEA levels and
increases anxiety, while infusion of low doses of a FAAH
inhibitor into the PFC reduces anxiety measures in the
elevated plus-maze [45]. Similarly, administration of a
CB1 receptor antagonist into the basolateral nucleus of
the amygdala (BLA) increases anxiety [46], while inhib-
ition of FAAH in the BLA reduces anxiety [47]. These
data suggest that enhancement of eCB signaling within
the PFC or amygdala can suppress anxiety, while dis-
ruption of eCB signaling in these structures can facili-
tate it. These findings are primarily based on the effects
of manipulating AEA signaling; however, no studies to
date have examined site-specific effects of MGL inhib-
ition. As anxiety is typically associated with reduced ac-
tivity in the PFC and enhanced activity in the
amygdala, it is not surprising that electrophysiological
evidence has demonstrated that eCB signaling in the
PFC can enhance neuronal activity through a suppres-
sion of γ-aminobutyric acid (GABA) release [48,49],
while suppressing glutamate release and excitability
within the amygdala [50-53]. Accordingly, the current
data would suggest that eCB signaling increases pre-
frontal cortical activity and suppresses amygdalar acti-
vation to dampen the expression of anxiety-like
behaviors in rodents.
Overall, the totality of data regarding the role of eCB
signaling in the modulation of anxiety behaviors suggest
eCBs play particularly important roles in reducing anx-
iety under stressful or anxiogenic contexts, but also may
contribute to constraining anxiety under non-stress con-
ditions. In addition to general measures of anxiety, there
is also a rapidly growing and very interesting literature
regarding the role of the eCB system in fear learning and
extinction; however, the complexity of this field is be-
yond the scope of the current review and there are sev-
eral detailed reviews which focus exclusively on this
topic (see [54] and [55]).
Depressive-like behaviors
Similar to the effects on anxiety behaviors, a role for
eCB signaling in depressive-like behaviors has also
been described. Augmentation of brain eCB signaling
has been suggested as a novel antidepressant strategy
by several authors [56-58]. In this section we will
review the key studies implicating eCB signaling in
depressive-like behaviors using acute models and tests –
studies utilizing chronic stress will be discussed in the
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CB1−/− mice have been shown to exhibit increases in
passive coping responses in the forced swim test [59]
and tail suspension test [60], although this is not a uni-
versal finding in the forced swim test at least [61,62].
Interestingly, CB1−/− mice have reduced hippocampal
brain-derived neurotrophic factor (BDNF) [59,60], and
normalization of hippocampal BDNF reverses the
depressive-like phenotype of these mice in the tail sus-
pension test [60]. These data, combined with data on
the enhanced stress-sensitivity of these mice discussed
below, suggest lifelong CB1 receptor deletion results in a
depressive-like phenotype, and because of these data, it
has been suggested that global CB1 deficient mice could
represent a valid animal model for major depression
[63,64]. However, more recent data indicate that select-
ive deletion of CB1 from glutamatergic neurons actually
has an antidepressant-like effect; whereas deletion of
CB1 from CaMKIIα-expressing principal forebrain neu-
rons or GABAergic neurons has no effect [65]. Interest-
ingly, combined genetic and pharmacological studies
have now revealed that the antidepressant effect of CB1
receptor deletion from cortical glutamatergic neurons is
driven by an increase in serotonin release as it is re-
versed by serotonin depletion [66]. Clearly, the role of
CB1 in the regulation of depressive-like behavior is com-
plex, and CB1 receptors expressed by different subsets
of neurons or neural circuits could even have opposing
effects on depressive behavior.
Similar to genetic deletion, pharmacological inhibition
of CB1 receptor activity has yielded complex and contra-
dictory results. Some studies have demonstrated an
antidepressant-like effect of the acute CB1 receptor
blockade in the forced swim test and/or tail suspension
test [67-69], while other reports indicate sub-chronic
CB1 receptor antagonist treatments are required for
consistent antidepressant-like effects [62]. In contrast,
several studies have demonstrated no effect of CB1 re-
ceptor blockade in the forced swim test and tail suspen-
sion test [23,59,61,70-73], while one study demonstrated
a depressive-like phenotype in the forced swim test after
chronic CB1 antagonist treatment [74]. Similarly, some
data support enhanced monoaminergic transmission
after an acute CB1 receptor blockade [69], and global
depletion of catecholamines can reverse the antidepres-
sant effect of acute CB1 receptor antagonism [66]. Add-
itionally, this effect of CB1 receptor antagonism is
driven by CB1 receptors on GABAergic neurons as it is
lost following selective deletion of CB1 from GABA
neuronal populations [66], suggesting that the blockade
of CB1 receptors on GABAergic neurons transiently in-
creases catecholamine transmission to produce behav-
ioral effects in the forced swim test. However, protractedadministration of a CB1 antagonist, which produces a ‘de-
pressive’-like phenotype, actually decreased monoamine
and BDNF levels [74], indicating that while acute effects
may suggest an antidepressant response, clearly sustained
inactivation of CB1 receptor signaling produces adverse
changes in emotional behavior, such as increased anxiety,
and evokes a biochemical signature similar to that seen
following chronic stress.
Although a significant discrepancy exists between the
antidepressant-like effects of the genetic and pharmaco-
logical CB1 receptor blockades, generally more consist-
ent findings have been published with regard to the
antidepressant-like effects of FAAH inhibition. Both
acute pharmacological and lifelong genetic deletion of
FAAH produce antidepressant-like effects in the forced
swim test and tail suspension test [33,34,70,71,75,76].
Some studies have found that these effects are more ro-
bust under highly aversive testing conditions [34]. Inter-
estingly, mice exposed to the forced swim test show
rapid reductions in PFC AEA levels, and direct PFC in-
jection of a FAAH inhibitor produced antidepressant-
like effects in the forced swim test [76]. FAAH inhibition
in the PFC increases the firing rate of serotonergic neu-
rons, and pharmacological serotonin depletion prevents
the antidepressant-like effects of FAAH inhibition in this
assay [76,77]. Taken together these data suggest FAAH
inhibition produces acute antidepressant-like effects via
activation of serotonergic and noradrenergic signaling
[58], and highlight the PFC again as a primary substrate
through which these effects are mediated.
To date, no data are currently available on the
antidepressant-like properties of MAGL inhibition, but
these are likely currently underway. This is a critical
question as it may reveal a second molecular target for
the pharmacological targeting eCB signaling to give an
antidepressant effect. Taken together, while the effects of
CB1 receptor antagonism or deletion may be equivocal
with respect to behavioral tests of stress coping, which is
reflective of depressive behavior, there is a high degree
of consistency among reports demonstrating that inhib-
ition of FAAH produces antidepressant-like effects in
rodent models.
Endocannabinoids and stress response modulation
The earliest studies into the role of eCB signaling in
stress response physiology utilized CB1−/− mice, which
exhibit a generally poorer coping response to stress. For
example, CB1−/− mice exhibit greater reductions in su-
crose intake during chronic unpredictable stress (CUS)
than wild-type mice [13], and show enhanced behavioral
inhibition and reduced ultrasonic vocalizations in re-
sponse to repeated bell stress [78]. Similarly, chronic re-
straint stress-induced anxiety behaviors in the elevated
plus-maze is augmented in CB1−/− mice, as is the
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[12]. After chronic social defeat stress, mice lacking CB1
receptors on single-minded-1-expressing neurons of the
basolateral amygdala and paraventricular hypothalamus
show enhanced anxiety in the open field [79]. Further-
more, CB1−/− mice exhibit reduced foot-shock induced
reinstatement of alcohol seeking behavior [80]. In con-
trast, other studies have found no effect of global CB1
deletion on anxiety behaviors after chronic social defeat
stress [17]. Overall, these data suggest CB1 receptor de-
ficiency impairs stress-coping responses and facilitates
the development of stress-induced psychopathology.
Several studies have also investigated the effects of
CB1 receptor antagonism on stress-induced behavioral
dysregulation. For example, acute CB1 receptor blockade
partially reverses the habituation of active coping re-
sponses observed during repeated restraint [81]. In
addition, CB1 receptor antagonism exaggerates acute re-
straint stress-induced deficits in sucrose preference [82],
with the magnitude of this effect intensifying with increas-
ing duration of restraint stress exposure. In contrast, one
study found an improved physical state and reduced anx-
iety in mice chronically treated with a CB1 receptor antag-
onist during CUS [68], while another found no effect of
repeated CB1 receptor antagonist treatment on anxiety or
hedonic measures after repeated social defeat stress [17].
In contrast to the above-mentioned behavioral studies,
several authors have reported remarkably consistent ef-
fects of stress on brain regional eCB levels. The most
consistent data indicate that acute and repeated restraint
stress decreases AEA levels in multiple limbic brain re-
gions but robustly in the amygdala [17,39,81,83-86]. In
some cases more repeated bouts of stress produced lar-
ger decreases in AEA levels [81], and the reduction lasts
at least 24 hours after termination of the last stressor
[86]. Interestingly, the degree of stress-induced AEA
reduction in the amygdala predicts stress-induced cor-
ticosterone elevation [85], suggesting a key role for
amygdala AEA in the regulation of stress response
physiology. The mechanisms regulating rapid reductions
in AEA are not well understood; however, reductions in
AEA after chronic stress are likely mediated via in-
creased FAAH activity [39,84]. The effects of acute and
repeated stress on 2-AG levels are also remarkably con-
sistent between studies and laboratories. In most cases
acute stress has little effect on 2-AG levels; however, re-
peated homotypic stress increases 2-AG levels in the
amygdala and other limbic brain regions [17,84,86-88],
while CUS has more variable effects [83], but often
showing a decrease in hippocampal 2-AG levels [89].
Interestingly, chronic corticosterone treatment also in-
creases amygdalar 2-AG levels [90]. These data suggest
that, while AEA appears to be acutely sensitive to mul-
tiple forms of stress and responds with reduced tissuelevels for possible protracted periods [85], 2-AG is in-
creased after repeated homotypic stress exposure only,
and this increase is transient and terminates after stres-
sor discontinuation [86,88]. Furthermore, after repeated
homotypic stress exposure, amygdalar 2-AG levels are
inversely correlated with corticosterone secretion, and
local antagonism of CB1 receptors within the basolateral
amygdala reverses stress habituation, suggesting one
function of the elevated 2-AG is to facilitate neuroendo-
crine habituation to repeated stress exposure [86].
Based on the totality of data reviewed this far, strong
evidence points to eCB signaling as a stress-buffering
system, and that one contribution to behavioral dysregulation
induced by stress is an AEA-deficient state. Based on
this simple interpretation several recent studies have
examined the therapeutic potential of eCB modulation
on stress-induced behavioral pathology. For example,
repeated treatment of mice with the MAGL inhibitor
JZL-184, which increases brain 2-AG levels, prevents
repeated restraint stress-induced anxiety measured in
the novelty-induced hypophagia assay [41]. Further-
more, both pharmacological and genetic inhibition of
FAAH prevents chronic restraint stress-induced anxiety
in the elevated plus-maze [39], as well as CUS-induced
anhedonia [91]. Possible mechanisms of action of eCB
augmentation in the mitigation of stress-induced be-
havioral dysregulation include modulation of hippo-
campal neurogenesis [92,93] and amygdala dendritic
hypertrophy [39].
Taken together, this review of the preclinical research
regarding the role of the eCB system in the regulation of
stress and emotional behavior creates a compelling argu-
ment that eCB signaling acts to constrain activation of
the stress response, and the ensuing neuroendocrine and
behavioral responses to stress. Acute disruption of CB1
receptor signaling reliably increases anxiety and activa-
tion of the hypothalamic–pituitary–adrenal (HPA) axis,
but has less consistent effects on depression-like behav-
ior (which may be reflective of the behavioral tests being
used), suggesting that there is an eCB tone acting to
keep these processes suppressed in non-stressful envir-
onmental conditions. As AEA is believed to mediate the
tonic actions of the eCB system, and because AEA levels
are reduced in response to stress, our current theory is
that AEA signaling acts as the ‘gatekeeper’ of sorts,
keeping stress and anxiety at bay, likely through its ac-
tions in the amygdala. In response to stress, particularly
stress of high emotional load or repeated exposure to a
common stressor, there is a mobilization of 2-AG, which
seems to be important for restricting the magnitude of
the stress response and aiding in normative recovery to
pre-stress levels of functioning. Accordingly, impair-
ments in eCB signaling, at either the ligand or the recep-
tor level, would likely result in either the induction of an
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the amygdala) under non-threatening conditions, or an
impairment in appropriate stress adaptation, both of
which could predispose an organism or individual to ex-
aggerated effects of stress. As such, these data would
suggest that eCB signaling could be compromised in
stress-related affective illnesses (such as major depres-
sion or post-traumatic stress disorder, both of which ap-
pear to be driven by maladaptive responses to stressful
life events), and that pharmacological enhancement of
eCB signaling could be a novel therapeutic avenue for
the treatment of these neuropsychiatric conditions. It
should be noted, however, that the majority of the stud-
ies investigating the effects of increased eCB signaling
largely focus on FAAH, and only a few recent studies
have begun to examine the effects of MAGL inhibition.
Given that there are noted pharmacokinetic, and pos-
sibly functional, differences between AEA and 2-AG
[4-6], it should not be immediately assumed that inhib-
ition of either enzyme will produce synonymous effects
(although the initial studies do suggest a high degree of
similarity). With the development of more specific tools
to target FAAH and MAGL exclusively, how these two
signaling molecules can be harnessed for the therapeutic
treatment of mood and anxiety disorders will become
clearer. The following section will discuss the transla-
tional and clinical evidence that has been gathered to
date and which supports the data generated from pre-
clinical studies and demonstrates the importance of the
eCB system in the regulation of stress responses and
emotional behavior in humans.
Role of endogenous cannabinoids in emotionality and
stress: clinical studies
In humans, centuries of cannabis use for the purposes of
controlling stress and anxiety strongly suggest that acti-
vation of the human eCB system serves a similar func-
tion to constrain stress and anxiety circuits as has been
demonstrated in animal models. In fact, the primary
reason as to why most individuals consume cannabis on
a regular basis is because of its ability to reduce feelings
of tension, promote relaxation and take the edge off
stressful life events [94]. More so, clinical studies employing
direct CB1 receptor agonists have shown potential thera-
peutic benefit in the treatment of both generalized anxiety
conditions and post-traumatic stress disorder (PTSD)
[95,96]. Interestingly, neuroimaging studies have replicated
the findings of preclinical studies, demonstrating that can-
nabinoid administration, or regular cannabis use, can effect-
ively dampen activation of the amygdala in response to
threatening or aversive stimuli [97-99]. Similarly, cerebral
blood flow studies have shown that cannabinoids can in-
crease activation of frontal cortical regions including the
anterior cingulate [100], which agrees with the rodentstudies demonstrating that CB1 receptor activation can
augment prefrontal cortical activity [48,49]. As such, from a
translational perspective these data support those generated
from animal studies demonstrating that activation of the
CB1 receptor in humans can reduce anxiety, deactivate the
amygdala and enhance prefrontal cortical function. With
respect to how the eCB system itself may function in these
regards, there are three lines of evidence that can be drawn
on to determine the putative role of this system in the en-
dogenous regulation of stress and emotional behavior: 1)
pharmacological challenge studies in which the CB1 recep-
tor is blocked to unmask the role of eCB signaling, 2) bio-
chemical studies investigating dynamic or steady-state
changes in eCB ligand content in response to stress or in
psychiatric conditions and 3) genetic studies investigating
the effect and possible role of functional polymorphisms in
the eCB system in response to stress or in psychiatric ill-
nesses. Each of these three lines of evidence will be
discussed below.
Pharmacological studies of CB1 receptor blockade in humans
As with the studies performed in rodents, the effects of
CB1 receptor antagonism in humans generally support
the hypothesis that eCB signaling negatively regulates
stress and anxiety. Clinical development of CB1 recep-
tor antagonists was initially advanced as a putative
mechanism to treat obesity, given that eCB signaling
promotes feeding and weight gain, and that a blockade
of eCB signaling in animals could mitigate the effects
of diet-induced obesity. In humans, clinical studies have
clearly demonstrated that blocking CB1 does provide
some therapeutic benefit in promoting weight loss
and alleviating metabolic abnormalities associated with
obesity; however, the first CB1 receptor antagonist
tested, rimonabant, developed specifically for this pur-
pose, was ultimately removed from the market due to
the development of anxiety and depressive symptoms
in a significant proportion of individuals [101,102]. In
fact, a meta-analysis of the four major clinical studies
performed with rimonabant found that there was ap-
proximately a threefold increase in the emergence of
anxiety symptoms in patients receiving rimonabant ver-
sus a placebo, and these studies were all performed on
individuals who had no history of psychiatric illness
[103]. The largest multi-center trial for rimonabant (in-
volving over 18,000 patients in 42 countries) similarly
found that there was a significant increase in neuro-
psychiatric side effects (in approximately one-third of
patients treated with rimonabant) and serious psychi-
atric side effects (which developed in roughly 1 in 40
individuals treated with rimonabant) following CB1 re-
ceptor antagonism [104]. One case report even dis-
cusses the de novo emergence of a profound bout of
melancholic depression, which occurred following
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cessation of drug administration [105]. Taken together,
these data clearly demonstrate that disruption of eCB
signaling in humans is capable of increasing the signs
of anxiety and depression, which supports the hypoth-
esis that eCB signaling in humans, as in rodents, acts
to dampen negative emotions.
Given the psychiatric disturbances found in the obesity
trials, it became quite difficult to ethically undertake an
in-depth study of the effects of CB1 receptor antagonism
in humans on facets of stress and emotional behavior.
However, a few studies have emerged and they have shed
some insight into the possible mechanisms. First, one re-
port found that high doses of rimonabant were capable
of increasing cortisol in some subjects [106], supporting
the animal studies indicating that eCB signaling nega-
tively regulates activation of the HPA axis [87]. Second,
a series of studies combining imaging and cognitive test-
ing demonstrated several interesting effects of CB1 re-
ceptor antagonism in humans, which could relate to its
ability to promote depression. Specifically, a 7-day treat-
ment regimen with a CB1 receptor antagonist was found
to blunt activation of reward circuits in the brain in re-
sponse to pleasurable stimuli [107], suggesting that defi-
cient eCB signaling could be a putative mechanism for
anhedonia in depression. Similarly, both a single dose of
rimonabant, as well as a 7-day treatment regimen of
rimonabant, were not found to affect mood significantly,
per se, but they were found to suppress the recall of emo-
tionally positive memories [108] and promote negative
bias in memory recall [109]. Both effects could result in a
negative emotional bias, a phenomenon commonly seen
in affective illnesses and known to be a risk factor for the
development of major depression.
Accordingly, these pharmacological studies in humans
demonstrate that disruption of eCB signaling is sufficient
to promote anxiety, increase HPA axis activity, impair
reward processes in the brain and enhance negative
emotional memory biases, all of which are all hallmark
signs of mood disorders. Thus, consistent with data
obtained from animal studies, these data support the
possibility that impaired eCB activity could be a predis-
posing factor for the development of stress-related
neuropsychiatric conditions.
Biochemical studies of the endogenous cannabinoid
system in mood and anxiety disorders
Another way to examine the eCB system in humans is
to measure eCB ligand content (AEA and 2-AG) in the
circulation of individuals to see how it is affected by
stress or altered in psychiatric disorders. Again, as was
seen in the pharmacological studies in humans, the data
generated to date are largely consistent with what has
been found in preclinical studies. First, several studieshave demonstrated that circulating levels of eCB mole-
cules are responsive to stress. Hill and colleagues [110]
demonstrated that exposure to the Trier social stress test
resulted in a significant increase in 2-AG concentrations
(and a small trend toward increased AEA concentra-
tions) in the circulation. Another study used parabolic
flight as a physiological stressor and found that it in-
creased 2-AG in the circulation, and that individuals
who did not mount a 2-AG response to the stress expos-
ure exhibited dramatically higher levels of cortisol,
suggesting that impairments in the natural induction of
an eCB response to stress produce heightened physio-
logical stress responses [111]. A more recent report that
also examined eCB responses in the circulation to the
Trier social stress test, demonstrated that circulating
levels of AEA, but not 2-AG, increased in response to
stress [112]. Interestingly, as in the parabolic flight study,
this study also reported that lower basal levels of AEA pre-
dicted increased HPA responses to stress, again suggesting
that eCB signaling negatively relates to the magnitude of
the stress response [112]. As such, these studies demon-
strate that eCB signaling in humans is responsive to stress,
and that failure of this system to be appropriately engaged
results in increased responses to stress.
With respect to direct associations of eCB levels with
mood and anxiety disorders, several studies do generally
seem to suggest that there is a frank deficiency in systemic
eCB signaling in several psychiatric conditions. Two inde-
pendent reports have found that circulating levels of 2-AG
(and in one study also AEA) are reduced in medication-free
women who have been diagnosed with major depression
[110,113]. Interestingly, circulating levels of AEA and 2-AG
were both found to be elevated in individuals with minor
depression [113], which suggests the hypothesis that active
recruitment of the eCB system may curb the development
of frank major depression. Like these reports, it has also
been found that in individuals who have undergone cardiac
surgery, the subsequent development of depression follow-
ing surgery was related to low levels of circulating AEA and
2-AG during the perioperative period [114].
Less research has directly examined eCB levels in
anxiety conditions. Interestingly, two studies have both
reported that basal levels of AEA in the circulation nega-
tively correlate with anxiety scores on clinical scales,
both in a healthy population [112] and in one composed
of individuals with major depression [113]. That is, indi-
viduals with higher levels of anxiety have lower levels of
circulating AEA. This is consistent with the preclinical
studies that have found relations between stress and
anxiety with low levels of AEA [39,45,81,85]. More inter-
estingly, a recent report found that circulating levels of
AEA are significantly reduced in individuals with PTSD,
compared to both healthy controls and those exposed to
trauma who did not develop PTSD [115]. This reduction
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upregulation of CB1 receptors throughout limbic circuits
in the brain [115], suggesting that: (1) circulating levels
of eCB may be reflective of centrally active eCBs and (2)
deficient eCB signaling may result in a compensatory
upregulation of CB1 receptors in the brain. Consistent
with this, we have recently demonstrated that PTSD is
associated with reduced levels of 2-AG in the circula-
tion, while lower AEA levels correlated with the inten-
sity of intrusive symptoms [116]. One recent report,
however, found the opposite effect with increased levels
of AEA and 2-AG in individuals with PTSD [117]; it is
not clear what the discrepancy is between this study and
the previous two, but could relate to differences in dis-
ease severity, as was seen in the minor versus major de-
pression study [113].
In sum, the majority of studies examining eCB levels
in humans have come to two conclusions that are largely
consistent with the preclinical literature. First, eCB sig-
naling is responsive to stress and deficient eCB activity
is associated with increased stress responses, suggesting
that eCB signaling constrains the magnitude of the stress
response. Second, basal eCB signaling appears to be re-
duced in individuals afflicted with stress-related psychi-
atric conditions, such as major depression or PTSD,
suggesting that impaired eCB signaling is related to the
development of these conditions. Whether the reduction
in eCB signaling is a predisposing factor or a burden of
the disease itself, is yet to be determined, as is whether
these changes in circulating eCB levels are reflective of
central eCB activity. The overall uniformity of these
findings supports the preclinical studies and suggests
that a functional eCB system is required for appropriate
adaptation and buffering of stress in humans.
Genetic studies of the endogenous cannabinoid signaling in
stress-responsive systems and stress-related disorders
An additional source of information that provides
insight into the role of eCB signaling in humans with re-
spect to stress and stress-related psychiatric illnesses is
genetic studies. With respect to the CB1 receptor (CNR1
gene), several studies to date have examined different
polymorphisms in the CNR1 gene and how they relate
to psychiatric illness, particularly depression. One poly-
morphism in particular, rs1049353, has received a fair
amount of attention. This allele has a major form (G
allele) and a minor form (A allele), and it would appear
that the A allele of this polymorphism exerts some level
of protection against stress and depression. Specifically,
one report has demonstrated in two separate popula-
tions that carriers of the A allele are protected against
the development of anhedonia and major depression in
adulthood following early life stress or abuse [118]. It
should be noted, however, that this effect was notentirely replicated by a second group, although they did
note that was a moderate risk reduction in carriers of
the A allele, but they suggested that this allele may be
more specific for anhedonia than depression, per se
[119]. Consistent with this idea that the minor allele of
this polymorphism is protective, Domschke and col-
leagues (2008) demonstrated that individuals carrying
the G allele were more likely to exhibit antidepressant
resistance than those with the A allele [120], suggesting
that the A allele may confer greater antidepressant re-
sponsiveness. This effect was found primarily in females,
and especially those that presented with melancholic de-
pression with high anxiety [120]. Interestingly, a replica-
tion study from another group found the opposite effect:
that if you were male and a G allele carrier you were
more likely to exhibit a better antidepressant response
than if you were an A allele carrier, suggesting that there
may be some sexual divergence in the role of the eCB
system in depression and antidepressant treatment
[121]. Of note, while not fully explored because the ef-
fect did not quite achieve statistical significance, another
report also found that presence of the A allele in this
polymorphism reduced the development of depression
in association with exposure to stressful life events
[122]. More interestingly, carriers of the G allele were
found to exhibit blunted limbic and striatal activation to
happy faces in imaging studies [123], which is a common
feature in depression and is associated with blunted re-
ward responsiveness and anhedonia. Taken together,
these studies would suggest that the A allele in the
rs1049353 polymorphism of the CNR1 gene results in
some level of protection against the development of de-
pression, particularly in response to stress exposure.
The one issue surrounding the rs1049353 polymorph-
ism is that there is no knowledge regarding whether it is
functional or not. This polymorphism is exonic, but it is
a synonymous polymorphism (in that the base pair sub-
stitution does not result in a difference in protein se-
quence), so it is unclear what effects it has, if any, on
CB1 receptor densities in vivo; however, it has been pos-
tulated that it may affect mRNA stability [120]. Based on
the preclinical literature and the general consensus that
eCB signaling confers protection against the effects of
stress, one possible interpretation is that the A allele of
this polymorphism could result in more stable mRNA
and a subsequent increase in protein expression and
function of the CB1 receptor in vivo; however, this re-
mains to be experimentally demonstrated.
Consistent with this hypothesis, other polymorphisms
in the CNR1 gene have been shown to have functional
effects on receptor expression. For example, carriers of
the C allele of another polymorphism in the CNR1 gene
(rs2023239) have been found to exhibit increased CB1
receptor binding both in post mortem brain tissue [124]
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imaging studies [125]. Interestingly, carriers of the C al-
lele (which have greater CB1 receptor density) have also
been found to have increased hippocampal volume
[126]. As hippocampal volume is known to be reduced
in major depression [127], and reduced hippocampal
volume is thought to be a risk factor in PTSD [128],
these data would suggest that polymorphisms in the
CNR1 gene that result in greater CB1 receptor activity
may result in increased hippocampal volume and thus
provide a neural substrate mediating a protective effect.
CB1 receptor activation is known to drive neurogenesis
in the hippocampus [129] and also protect hippocampal
neurons from excitotoxic damage [130], and so it is rea-
sonable to predict that greater CB1 receptor densities
could result in enhanced hippocampal function. Unfor-
tunately, as there are no studies to date examining the
effect of the rs2023239 polymorphism on psychiatric ill-
ness it is not known if this polymorphism has any effect
on disease vulnerability. Future studies should thoroughly
investigate the role of this polymorphism in psychiatric
illness, and also determine if the rs1049353 polymorphism
has a similar effect on CB1 receptor density in humans
to understand how these gene variants could impact
disease progression.
In addition to this abundance of work on the rs1049353
polymorphism, a scattering of other polymorphisms of the
CNR1 gene have been investigated. For examples, the T al-
lele in the rs7766029 polymorphism is significantly associ-
ated with the development of depression following
increasing exposure to stressful life events [122]. With re-
spect to anxiety, the only study that has been done with
the CNR1 gene is one that identified an epistatic relation
between CNR1 and the serotonin transporter. Specifically,
they found that individuals who possessed the short vari-
ant of the serotonin transporter, coupled to the GG homo-
zygous allele of the rs2180619 polymorphism of the CNR1
gene, exhibited dramatically higher levels of anxiety [131].
They suggested that this GG allele resulted in lower levels
of CB1 receptor expression, which could result in excess
serotonin release, and when coupled with the short sero-
tonin transporter allele (which exhibits impaired 5-HT
clearance from the synapse), could result in excessive sero-
tonin signaling that would produce heightened levels of
anxiety [131]. It is of interest to note that this model is
consistent with the recent findings that CB1 receptor dele-
tion exclusively from serotonergic neurons was sufficient
to produce a state of anxiety [17], suggesting that interac-
tions between eCB signaling and serotonin are indeed
important for the regulation of anxiety. While very intri-
guing, all of these polymorphisms require more research
to validate that these effects are replicable and more im-
portantly, what the functional effects of all these polymor-
phisms are. Regardless, these data do indicate that geneticvariation in the CB1 receptor does relate to changes in
emotional behavior and thus further supports the evidence
that eCB signaling is an important contributor of emo-
tional behavior in humans.
One of the most interesting gene variants in the eCB
system studied to date is a functional polymorphism in
the FAAH gene. The C385A polymorphism of FAAH is
when an A base is substituted for a C base in the se-
quence, resulting in a non-synonymous change of pro-
line for threonine in the FAAH protein [132]. The A
allele results in enhanced proteolytic degradation of
FAAH [132], which results in lower levels of the FAAH
protein and activity [133] and higher levels of AEA in
the circulation [134]. Interestingly, carriers of the A al-
lele of this FAAH polymorphism exhibit blunted activa-
tion of the amygdala in response to threat cues and
enhanced activation of the ventral striatum in response
to reward-related cues [135]. That is, stress-induced acti-
vation of the amygdala is reduced in those who have ele-
vated AEA levels, and striatal responses to reward are
higher. Subsequent research on this polymorphism has
also revealed that A carriers exhibit lower levels of trait
anxiety, reduced stress reactivity and also demonstrate
more rapid habituation of amygdalar activation in re-
sponse to aversive cues than C carriers [136]. However,
one recent report found the exact opposite effect and
showed increased startle reaction in A carriers to un-
pleasant images, suggestive of greater amygdala activa-
tion; however, the authors did not measure amygdala
activation through neuroimaging techniques and based
their assumptions purely on behavioral outcomes [137].
The reason for this putative discrepancy, and possible
interactions with life stress, should be considered in fu-
ture studies. The findings that high levels of AEA reduce
amygdala reactivity to stress, reduce trait anxiety and
promote habituation to stress are highly consistent with
the preclinical studies detailed above.
Conclusions
Ultimately, these studies on eCB signaling in humans
generally agree with the preclinical findings and sug-
gest that in humans, eCB signaling is important for
regulating stress and emotions. Elevated eCB signaling
seems to be associated with reduced stress and anxiety,
while impaired eCB signaling is associated with greater
vulnerability to stress, anxiety and depression. The extent
to which these findings can be used on a translational plat-
form to understand the pathophysiology of stress-related
psychiatric conditions in humans has yet to be deter-
mined, but the convergence of the preclinical and clinical
findings detailed here strongly suggests that this should be
a field of focused research in coming years.
We propose several areas of research that would help to
fill gaps in knowledge and guide research to further
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respect to the development of novel therapeutics for mood
and anxiety disorders. First, what are the relative benefits
and drawbacks of selective AEA and 2-AG augmentation,
and would dual inhibition of FAAH and MAGL be a more
efficacious approach? Second, what are the downstream
signaling mechanisms responsible for the anxiolytic, anti-
depressant and anti-stress effects of FAAH and MAGL in-
hibition? Third, what is the precise molecular mechanism
subserving the context-dependency of eCB modulation of
anxiety behaviors? We and others have suggested a key
factor is the reduction in AEA signaling that occurs under
stressful conditions [138]; however, the mechanisms sub-
serving these effects are not well understood. Fourth, are
eCB augmenting agents able to prevent, and more import-
antly, reverse, stress-induced pathology? If effective, do
they extend beyond behavioral effects to metabolic, car-
diac and immune effects of chronic stress? Is there a
causal relationship between stress-induced adaptations in
eCB levels and stress-induced pathology? Finally, are there
other molecular targets that can be utilized to enhance
eCB signaling for therapeutic gain? With regard to this last
question, very recent studies suggest that, in addition to
FAAH and MAGL, COX-2 could also be a viable target
for eCB augmentation and have anxiolytic potential [136].
Taken together, there is a very compelling argument
forming that eCB signaling is a vital component of stress-
regulatory systems in mammals, including rodents and
humans. As such, the eCB system represents an ideal sys-
tem for translational research since human studies gener-
ally corroborate animal studies. Animal studies can delve
further into the mechanism and inform future clinical
studies investigating the role of eCB signaling in treating
psychiatric disorders. Only time, and clinical trials, will tell
if this system truly represents a novel therapeutic target
for mood and anxiety disorders.
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